{"protocolSection":{"identificationModule":{"nctId":"NCT00753714","orgStudyIdInfo":{"id":"D4200L00012"},"secondaryIdInfos":[{"id":"EUDRACT n° 2007-004521-22"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine","officialTitle":"Phase II, Randomised, Double-blind, Two-arm, Parallel Study of Vandetanib (ZACTIMA™ , ZD6474) Plus Gemcitabine (Gemzar® ) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.","acronym":"ZELIG"},"statusModule":{"statusVerifiedDate":"2016-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-10"},"primaryCompletionDateStruct":{"date":"2011-04","type":"ACTUAL"},"completionDateStruct":{"date":"2011-12","type":"ACTUAL"},"studyFirstSubmitDate":"2008-09-15","studyFirstSubmitQcDate":"2008-09-15","studyFirstPostDateStruct":{"date":"2008-09-16","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-08-29","resultsFirstSubmitQcDate":"2012-08-29","resultsFirstPostDateStruct":{"date":"2012-09-28","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-08-30","lastUpdatePostDateStruct":{"date":"2016-10-17","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Genzyme, a Sanofi Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The primary objective of this study is to demonstrate an improvement in Progression-Free Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine plus placebo in chemonaïve (not including an adjuvant regimen) patients aged ≥ 70 years with advanced NSCLC."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"],"keywords":["ZD6474","VANDETANIB","ZACTIMA","ADVANCED","NSCLC","LUNG CANCER","ELDERLY PATIENTS","GEMCITABINE","PHASE II","RANDOMIZED","DOUBLE-BLIND","histologically or cytologically-confirmed advanced (stage IIIB with supraclavicular lymph node metastases or pleural effusion or stage IV) NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":124,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A","type":"EXPERIMENTAL","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.","interventionNames":["Drug: ZD6474, Vandetanib","Drug: Gemcitabine"]},{"label":"B","type":"PLACEBO_COMPARATOR","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.","interventionNames":["Drug: Placebo to Match ZD6474, Vandetanib","Drug: Gemcitabine"]}],"interventions":[{"type":"DRUG","name":"ZD6474, Vandetanib","description":"100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first","armGroupLabels":["A"],"otherNames":["Zactima"]},{"type":"DRUG","name":"Placebo to Match ZD6474, Vandetanib","description":"100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first","armGroupLabels":["B"],"otherNames":["Zactima"]},{"type":"DRUG","name":"Gemcitabine","description":"administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first","armGroupLabels":["A","B"],"otherNames":["Gemzar"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival","timeFrame":"Oct 2008- dec 2011"}],"secondaryOutcomes":[{"measure":"Overall Survival","timeFrame":"Oct 2008- dec 2011"},{"measure":"Overall Objective Response","timeFrame":"Oct 2008- dec 2011"},{"measure":"Duration of Response","timeFrame":"Oct 2008- dec 2011"},{"measure":"The Safety and Tolerability Profile of ZD6474 (Vandetanib) in Combination With Gemcitabine","description":"The Safety and Tolerability Profile of ZD6474 (Vandetanib) in Combination With Gemcitabine is defined as the number of Adverse Events which includes any symptoms and/or Clinically Significant Laboratory or Vital Signs Abnormalities, and/or ECGs Changes","timeFrame":"Oct 2008- Dec 2011"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologic or cytologic confirmation of advanced NSCLC (stage IIIB with supraclavicular lymph node metastases or pleural effusion or stage IV) on entry into study\n* One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral CT scan or 20 mm with conventional techniques according to RECIST criteria\n* Chemotherapy-naïve (prior chemotherapy in the adjuvant setting completed more than 3 months before the trial entry is accepted).\n* Female or male aged 70 years or above\n\nExclusion Criteria:\n\n* Patients must not have received prior anti-cancer therapy except in the adjuvant setting\n* Inadequate end-organ function or Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial\n* Significant cardiovascular event (e.g. myocardial infarction, superior vena cava \\[SVC\\] syndrome, New York Heart Association \\[NYHA\\] classification of heart disease ³2) within 3 months before entry, or presence of cardiac disease that in the opinion of\n* History of arrhythmia or QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG","healthyVolunteers":false,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Sciences & Operations","affiliation":"Sanofi","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Meldola","state":"(fc)","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"Research Site","city":"Avellino","state":"AV","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"Research Site","city":"Bari","state":"BA","country":"Italy","geoPoint":{"lat":41.12066,"lon":16.86982}},{"facility":"Research Site","city":"Treviglio","state":"BG","country":"Italy","geoPoint":{"lat":45.52081,"lon":9.59102}},{"facility":"Research Site","city":"Bologna","state":"BO","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Research Site","city":"Genova","state":"GE","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Research Site","city":"Taormina","state":"ME","country":"Italy","geoPoint":{"lat":37.85358,"lon":15.28851}},{"facility":"Research Site","city":"Milan","state":"MI","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Perugia","state":"PG","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Research Site","city":"Ravenna","state":"RA","country":"Italy","geoPoint":{"lat":44.41344,"lon":12.20121}},{"facility":"Research Site","city":"Roma","state":"Roma","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Research Site","city":"Trento","state":"TN","country":"Italy","geoPoint":{"lat":46.06787,"lon":11.12108}},{"facility":"Research Site","city":"Orbassano","state":"TO","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Research Site","city":"Udine","state":"UD","country":"Italy","geoPoint":{"lat":46.0693,"lon":13.23715}},{"facility":"Research Site","city":"Padua","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}}]},"referencesModule":{"references":[{"pmid":"18165633","type":"BACKGROUND","citation":"Gridelli C. Treatment of advanced non small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. J Clin Oncol. 2008 Jan 1;26(1):13-5. doi: 10.1200/JCO.2007.14.1820. No abstract available."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"A total of 124 patients have been enrolled in a period of 19 months in 17 actively recruiting Oncologic Medical Department in Italy.","groups":[{"id":"FG000","title":"ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued."},{"id":"FG001","title":"Placebo to Match ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"63"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"62"}]}],"dropWithdraws":[{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"34"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"18"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued."},{"id":"BG001","title":"Placebo to Match ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"124"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"75.03","spread":"3.34"},{"groupId":"BG001","value":"75.48","spread":"3.49"},{"groupId":"BG002","value":"75.25","spread":"3.41"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"34"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"90"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Oct 2008- dec 2011","groups":[{"id":"OG000","title":"ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued."},{"id":"OG001","title":"Placebo to Match ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"183","lowerLimit":"116","upperLimit":"214"},{"groupId":"OG001","value":"169","lowerLimit":"95","upperLimit":"194"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Oct 2008- dec 2011","groups":[{"id":"OG000","title":"ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued"},{"id":"OG001","title":"Placebo to Match ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"262","lowerLimit":"170","upperLimit":"356"},{"groupId":"OG001","value":"305","lowerLimit":"214","upperLimit":"355"}]}]}]},{"type":"SECONDARY","title":"Overall Objective Response","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Oct 2008- dec 2011","groups":[{"id":"OG000","title":"ZD6474 ( (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued."},{"id":"OG001","title":"Placebo to Match ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Oct 2008- dec 2011","groups":[{"id":"OG000","title":"ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued"},{"id":"OG001","title":"Placebo to Match ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"225","lowerLimit":"175","upperLimit":"NA","comment":"Too few participants experienced event to compute upper limit of CI, i.e.sample analyzed is to small compared with the initial statistical plan or when less than 50% of the subjects are available for analysis"},{"groupId":"OG001","value":"214","lowerLimit":"124","upperLimit":"232"}]}]}]},{"type":"SECONDARY","title":"The Safety and Tolerability Profile of ZD6474 (Vandetanib) in Combination With Gemcitabine","description":"The Safety and Tolerability Profile of ZD6474 (Vandetanib) in Combination With Gemcitabine is defined as the number of Adverse Events which includes any symptoms and/or Clinically Significant Laboratory or Vital Signs Abnormalities, and/or ECGs Changes","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Adverse Events","timeFrame":"Oct 2008- Dec 2011","groups":[{"id":"OG000","title":"ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued"},{"id":"OG001","title":"Placebo to Match ZD6474 (Vandetanib),Gemcitabine","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"381"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"ZD6474 (Gemcitabine), Vandetanib","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.","seriousNumAffected":26,"seriousNumAtRisk":61,"otherNumAffected":59,"otherNumAtRisk":61},{"id":"EG001","title":"Placebo to Match ZD6474 (Gemcitabine), Vandetanib","description":"Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued","seriousNumAffected":25,"seriousNumAtRisk":63,"otherNumAffected":62,"otherNumAtRisk":63}],"seriousEvents":[{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":61},{"groupId":"EG001","numAffected":9,"numAtRisk":63}]},{"term":"Pulmunary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":61},{"groupId":"EG001","numAffected":3,"numAtRisk":63}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Pulmunary Oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"acute pulmunary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"chronic obstructive pulmunary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Respiratory Distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Acute Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Cardiac Failure Acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Pleuropericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Cerebral Infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Depressed Level Of Consciuosness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Cerebral Ischemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":2,"numAtRisk":63}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Uraniry Retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Skin Toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Eye Disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Femur Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Weight Decrease","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Muscoloskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Ear Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":0,"numAtRisk":63}]},{"term":"Malignant Melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Oesophageal Adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Confusional State","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":3,"numAtRisk":63}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Infarction","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Peripheral Ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Vena Cava Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Hepatic Cirrhosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]}],"otherEvents":[{"term":"pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":61},{"groupId":"EG001","numAffected":17,"numAtRisk":63}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":61},{"groupId":"EG001","numAffected":15,"numAtRisk":63}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":61},{"groupId":"EG001","numAffected":13,"numAtRisk":63}]},{"term":"Dispnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":61},{"groupId":"EG001","numAffected":19,"numAtRisk":63}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":61},{"groupId":"EG001","numAffected":10,"numAtRisk":63}]},{"term":"PLT count decrease","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":61},{"groupId":"EG001","numAffected":9,"numAtRisk":63}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":61},{"groupId":"EG001","numAffected":12,"numAtRisk":63}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":61},{"groupId":"EG001","numAffected":14,"numAtRisk":63}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":61},{"groupId":"EG001","numAffected":4,"numAtRisk":63}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":61},{"groupId":"EG001","numAffected":9,"numAtRisk":63}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":61},{"groupId":"EG001","numAffected":8,"numAtRisk":63}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":61},{"groupId":"EG001","numAffected":7,"numAtRisk":63}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":61},{"groupId":"EG001","numAffected":5,"numAtRisk":63}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":61},{"groupId":"EG001","numAffected":17,"numAtRisk":63}]},{"term":"Hypokaliemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":61},{"groupId":"EG001","numAffected":7,"numAtRisk":63}]},{"term":"Mucosal Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":61},{"groupId":"EG001","numAffected":4,"numAtRisk":63}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":61},{"groupId":"EG001","numAffected":12,"numAtRisk":63}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":61},{"groupId":"EG001","numAffected":15,"numAtRisk":63}]},{"term":"Pulmunary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":61},{"groupId":"EG001","numAffected":3,"numAtRisk":63}]},{"term":"Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Neutrphil Count Decreased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":61},{"groupId":"EG001","numAffected":2,"numAtRisk":63}]},{"term":"Aspartate Aminotransferase Inctìreased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":61},{"groupId":"EG001","numAffected":1,"numAtRisk":63}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":61},{"groupId":"EG001","numAffected":4,"numAtRisk":63}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":61},{"groupId":"EG001","numAffected":2,"numAtRisk":63}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":61},{"groupId":"EG001","numAffected":3,"numAtRisk":63}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":61},{"groupId":"EG001","numAffected":4,"numAtRisk":63}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":61},{"groupId":"EG001","numAffected":4,"numAtRisk":63}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."},"pointOfContact":{"title":"Trial Transparency Team","organization":"Sanofi","email":"Contact-US@sanofi.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D010996","term":"Pleural Effusion"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D010995","term":"Pleural Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C452423","term":"vandetanib"},{"id":"D000093542","term":"Gemcitabine"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"}]}},"hasResults":true}